Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?

• Published in: Médecine et maladies infectieuses Vol. 48; no. 4; pp. 294 - 297
• Main Authors: Gaye, E., Le Bot, A., Talarmin, J.P., Le Calloch, R., Belaz, S., Dupont, M., Tattevin, P.
• Format: Journal Article
• Language: English
• Published: France Elsevier SAS 01-06-2018; Elsevier Masson
• Subjects: Aged; Aspergillose cérébrale; Brain Diseases - chemically induced; Brain Diseases - microbiology; Cancer; Cerebral aspergillosis; Chronic lymphocytic leukemia; Human health and pathology; Humans; Ibrutinib; Infectious diseases; Leucémie lymphoïde chronique; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Life Sciences; Male; Neuroaspergillosis - chemically induced; Opportunistic Infections - chemically induced; Pharmaceutical sciences; Pharmacology; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Chronic lymphocytic leukemia; Leucémie lymphoïde chronique; Ibrutinib; Cerebral aspergillosis; Aspergillose cérébrale
• ISSN: 0399-077X; 1769-6690
• DOI: 10.1016/j.medmal.2018.01.003

Ibrutinib is a novel oral covalent inhibitor of Bruton's tyrosine kinase (BTK). It has been approved for the treatment of relapsing chronic lymphocytic leukemia (CLL), or CLL with high-risk cytogenetic abnormalities. Several cases of invasive aspergillosis have recently been reported in ibrutinib-treated patients. We report two cases of cerebral aspergillosis in CLL patients treated with ibrutinib.